PUBLICATIONS Archives - Sagimet Biosciences

Graviton

0

PUBLICATIONS

February 13, 2018

Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN (Presented at the Keystone Symposium on Organ Crosstalk in Obesity and NAFLD, Jan. 21-25, 2018 Keystone, CO, Poster #3028)

Graviton

0

PUBLICATIONS

October 23, 2017

Fatty Acid Synthase Inhibitor TVB-3664 Reverses Multiple Components of Diet Induced Nonalcoholic Steatohepatitis in Mice Treated With or Without Co-Administered Pirfenidone and Reduces Collagen Accumulation in Bleomycin-Induced Murine Skin Fibrosis (Presented at The Liver Meeting 2017®, Washington, DC, Oct 20-24, Presidential Poster of Distinction, Abstract #1994).

Graviton

0

PUBLICATIONS

October 23, 2017

Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans (Presented at The Liver Meeting 2017®, Washington, DC, Oct 20-24, Abstract #1972).

Graviton

0

PUBLICATIONS

May 2, 2017

Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for NASH treatment (Presented at The International Liver Congress, Amsterdam, NL April 18-23, 2017, Late Breaking Abstract LB427)

Graviton

0

PUBLICATIONS

December 12, 2016

Heavily Pre-Treated Breast Cancer Patients Show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640 in Combination with Paclitaxel. (Presented at the San Antonio Breast Cancer Symposium on Saturday Dec. 10, 2016, abstract number P6-11-09)

Graviton

0

PUBLICATIONS

November 11, 2016

Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans (Presidential Poster of Distinction presented at the AASLD Meeting on Sunday November 13, 2016, Abstract #1547)

Graviton

0

PUBLICATIONS

November 8, 2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640 (Presented at the NCRI Cancer Conference on Tuesday Nov. 8, 2016)

Graviton

0

PUBLICATIONS

June 1, 2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 (Poster and Poster Discussion Sessions at the ASCO Meeting on Sunday June 5, 2016, Abstract #2512, Board #212)

Graviton

0

PUBLICATIONS

April 19, 2016

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study (Poster Presentation at AACR Meeting on Monday Apr 18, 2016 1:00 PM, Abstract number LB-214)

Graviton

0

PUBLICATIONS

April 19, 2016

Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640 (Poster Presentation at AACR Meeting on Wednesday, April 20, 2016, Abstract number 4743)

PUBLICATIONS

Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN (Presented at the Keystone Symposium on Organ Crosstalk in Obesity and NAFLD, Jan. 21-25, 2018 Keystone, CO, Poster #3028)

Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans (Presented at The Liver Meeting 2017®, Washington, DC, Oct 20-24, Abstract #1972).

Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for NASH treatment (Presented at The International Liver Congress, Amsterdam, NL April 18-23, 2017, Late Breaking Abstract LB427)

Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans (Presidential Poster of Distinction presented at the AASLD Meeting on Sunday November 13, 2016, Abstract #1547)

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640 (Presented at the NCRI Cancer Conference on Tuesday Nov. 8, 2016)

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 (Poster and Poster Discussion Sessions at the ASCO Meeting on Sunday June 5, 2016, Abstract #2512, Board #212)

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study (Poster Presentation at AACR Meeting on Monday Apr 18, 2016 1:00 PM, Abstract number LB-214)

Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640 (Poster Presentation at AACR Meeting on Wednesday, April 20, 2016, Abstract number 4743)

Site Map

Contact Us